Does the media favor IDYA or CTMX?

In the previous week, IDEAYA Biosciences had 4 more articles in the media than CytomX Therapeutics. MarketBeat recorded 7 mentions for IDEAYA Biosciences and 3 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 0.18 beat IDEAYA Biosciences' score of 0.11 indicating that CytomX Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral CytomX Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer CTMX or IRON?

In the previous week, Disc Medicine had 6 more articles in the media than CytomX Therapeutics. MarketBeat recorded 9 mentions for Disc Medicine and 3 mentions for CytomX Therapeutics. Disc Medicine's average media sentiment score of 0.44 beat CytomX Therapeutics' score of 0.18 indicating that Disc Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Disc Medicine 2 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ELVN or CTMX?

In the previous week, Enliven Therapeutics had 1 more articles in the media than CytomX Therapeutics. MarketBeat recorded 4 mentions for Enliven Therapeutics and 3 mentions for CytomX Therapeutics. Enliven Therapeutics' average media sentiment score of 0.83 beat CytomX Therapeutics' score of 0.18 indicating that Enliven Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CytomX Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer MLYS or CTMX?

In the previous week, Mineralys Therapeutics had 11 more articles in the media than CytomX Therapeutics. MarketBeat recorded 14 mentions for Mineralys Therapeutics and 3 mentions for CytomX Therapeutics. Mineralys Therapeutics' average media sentiment score of 0.79 beat CytomX Therapeutics' score of 0.18 indicating that Mineralys Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mineralys Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CytomX Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor CTMX or IMNM?

In the previous week, Immunome had 3 more articles in the media than CytomX Therapeutics. MarketBeat recorded 6 mentions for Immunome and 3 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 0.18 beat Immunome's score of 0.18 indicating that CytomX Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Immunome 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

CytomX Therapeutics (CTMX) Competitors

$3.22 +0.06 (+1.90%)

Closing price 04:00 PM Eastern

Extended Trading

$3.18 -0.04 (-1.12%)

As of 07:59 PM Eastern

Compare

CTMX vs. IDYA, IRON, ELVN, MLYS, and IMNM

Should you buy CytomX Therapeutics stock or one of its competitors? MarketBeat compares CytomX Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CytomX Therapeutics include IDEAYA Biosciences (IDYA), Disc Medicine (IRON), Enliven Therapeutics (ELVN), Mineralys Therapeutics (MLYS), and Immunome (IMNM). These companies are all part of the "pharmaceutical products" industry.

How does CytomX Therapeutics compare to IDEAYA Biosciences?

IDEAYA Biosciences (NASDAQ:IDYA) and CytomX Therapeutics (NASDAQ:CTMX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

IDEAYA Biosciences presently has a consensus target price of $50.69, indicating a potential upside of 78.48%. CytomX Therapeutics has a consensus target price of $12.10, indicating a potential upside of 275.78%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CytomX Therapeutics is more favorable than IDEAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.82
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

In the previous week, IDEAYA Biosciences had 4 more articles in the media than CytomX Therapeutics. MarketBeat recorded 7 mentions for IDEAYA Biosciences and 3 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 0.18 beat IDEAYA Biosciences' score of 0.11 indicating that CytomX Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
CytomX Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

98.3% of IDEAYA Biosciences shares are held by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are held by institutional investors. 4.7% of IDEAYA Biosciences shares are held by company insiders. Comparatively, 6.6% of CytomX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

CytomX Therapeutics has lower revenue, but higher earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$218.71M	11.41	-$113.70M	-$1.60	N/A
CytomX Therapeutics	$76.20M	7.19	-$17.37M	-$0.41	N/A

IDEAYA Biosciences has a beta of -0.05, meaning that its stock price is 105% less volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.08, meaning that its stock price is 108% more volatile than the broader market.

IDEAYA Biosciences has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -166.40%. IDEAYA Biosciences' return on equity of -14.24% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	N/A	-14.24%	-13.09%
CytomX Therapeutics	-166.40%	-36.61%	-28.02%

Summary

CytomX Therapeutics beats IDEAYA Biosciences on 9 of the 17 factors compared between the two stocks.

How does CytomX Therapeutics compare to Disc Medicine?

CytomX Therapeutics (NASDAQ:CTMX) and Disc Medicine (NASDAQ:IRON) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation.

CytomX Therapeutics has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$76.20M	7.19	-$17.37M	-$0.41	N/A
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A

Disc Medicine has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -166.40%. CytomX Therapeutics' return on equity of -36.61% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-166.40%	-36.61%	-28.02%
Disc Medicine	N/A	-36.94%	-33.88%

67.8% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 83.7% of Disc Medicine shares are owned by institutional investors. 6.6% of CytomX Therapeutics shares are owned by insiders. Comparatively, 3.8% of Disc Medicine shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

CytomX Therapeutics has a beta of 2.08, indicating that its share price is 108% more volatile than the broader market. Comparatively, Disc Medicine has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market.

In the previous week, Disc Medicine had 6 more articles in the media than CytomX Therapeutics. MarketBeat recorded 9 mentions for Disc Medicine and 3 mentions for CytomX Therapeutics. Disc Medicine's average media sentiment score of 0.44 beat CytomX Therapeutics' score of 0.18 indicating that Disc Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Disc Medicine	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CytomX Therapeutics presently has a consensus price target of $12.10, indicating a potential upside of 275.78%. Disc Medicine has a consensus price target of $105.30, indicating a potential upside of 49.68%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe CytomX Therapeutics is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

CytomX Therapeutics beats Disc Medicine on 11 of the 16 factors compared between the two stocks.

How does CytomX Therapeutics compare to Enliven Therapeutics?

Enliven Therapeutics (NASDAQ:ELVN) and CytomX Therapeutics (NASDAQ:CTMX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

CytomX Therapeutics has higher revenue and earnings than Enliven Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
CytomX Therapeutics	$76.20M	7.19	-$17.37M	-$0.41	N/A

Enliven Therapeutics has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.08, meaning that its share price is 108% more volatile than the broader market.

95.1% of Enliven Therapeutics shares are held by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are held by institutional investors. 3.0% of Enliven Therapeutics shares are held by company insiders. Comparatively, 6.6% of CytomX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Enliven Therapeutics presently has a consensus target price of $61.80, suggesting a potential upside of 71.52%. CytomX Therapeutics has a consensus target price of $12.10, suggesting a potential upside of 275.78%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe CytomX Therapeutics is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

In the previous week, Enliven Therapeutics had 1 more articles in the media than CytomX Therapeutics. MarketBeat recorded 4 mentions for Enliven Therapeutics and 3 mentions for CytomX Therapeutics. Enliven Therapeutics' average media sentiment score of 0.83 beat CytomX Therapeutics' score of 0.18 indicating that Enliven Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CytomX Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Enliven Therapeutics has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -166.40%. Enliven Therapeutics' return on equity of -21.04% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-21.04%	-20.41%
CytomX Therapeutics	-166.40%	-36.61%	-28.02%

Summary

CytomX Therapeutics beats Enliven Therapeutics on 9 of the 15 factors compared between the two stocks.

How does CytomX Therapeutics compare to Mineralys Therapeutics?

Mineralys Therapeutics (NASDAQ:MLYS) and CytomX Therapeutics (NASDAQ:CTMX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Mineralys Therapeutics currently has a consensus price target of $49.33, indicating a potential upside of 96.86%. CytomX Therapeutics has a consensus price target of $12.10, indicating a potential upside of 275.78%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CytomX Therapeutics is more favorable than Mineralys Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

CytomX Therapeutics has higher revenue and earnings than Mineralys Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A
CytomX Therapeutics	$76.20M	7.19	-$17.37M	-$0.41	N/A

In the previous week, Mineralys Therapeutics had 11 more articles in the media than CytomX Therapeutics. MarketBeat recorded 14 mentions for Mineralys Therapeutics and 3 mentions for CytomX Therapeutics. Mineralys Therapeutics' average media sentiment score of 0.79 beat CytomX Therapeutics' score of 0.18 indicating that Mineralys Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mineralys Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CytomX Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

84.5% of Mineralys Therapeutics shares are held by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are held by institutional investors. 18.9% of Mineralys Therapeutics shares are held by company insiders. Comparatively, 6.6% of CytomX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Mineralys Therapeutics has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -166.40%. Mineralys Therapeutics' return on equity of -27.92% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mineralys Therapeutics	N/A	-27.92%	-26.98%
CytomX Therapeutics	-166.40%	-36.61%	-28.02%

Mineralys Therapeutics has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.08, meaning that its stock price is 108% more volatile than the broader market.

Summary

CytomX Therapeutics beats Mineralys Therapeutics on 9 of the 16 factors compared between the two stocks.

How does CytomX Therapeutics compare to Immunome?

CytomX Therapeutics (NASDAQ:CTMX) and Immunome (NASDAQ:IMNM) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

67.8% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 44.6% of Immunome shares are owned by institutional investors. 6.6% of CytomX Therapeutics shares are owned by insiders. Comparatively, 7.2% of Immunome shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

CytomX Therapeutics has higher revenue and earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$76.20M	7.19	-$17.37M	-$0.41	N/A
Immunome	$6.94M	323.27	-$212.39M	-$2.38	N/A

In the previous week, Immunome had 3 more articles in the media than CytomX Therapeutics. MarketBeat recorded 6 mentions for Immunome and 3 mentions for CytomX Therapeutics. CytomX Therapeutics' average media sentiment score of 0.18 beat Immunome's score of 0.18 indicating that CytomX Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Immunome	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

CytomX Therapeutics has a beta of 2.08, suggesting that its stock price is 108% more volatile than the broader market. Comparatively, Immunome has a beta of 2.04, suggesting that its stock price is 104% more volatile than the broader market.

CytomX Therapeutics presently has a consensus price target of $12.10, suggesting a potential upside of 275.78%. Immunome has a consensus price target of $33.17, suggesting a potential upside of 67.42%. Given CytomX Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe CytomX Therapeutics is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Immunome has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -166.40%. CytomX Therapeutics' return on equity of -36.61% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-166.40%	-36.61%	-28.02%
Immunome	N/A	-51.15%	-47.32%

Summary

CytomX Therapeutics beats Immunome on 12 of the 17 factors compared between the two stocks.

Get CytomX Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTMX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTMX vs. The Competition

Export

Metric	CytomX Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$537.79M	$3.24B	$6.47B	$12.54B
Dividend Yield	N/A	2.38%	2.69%	5.22%
P/E Ratio	-7.85	17.78	22.39	24.18
Price / Sales	7.19	315.63	520.79	112.26
Price / Cash	N/A	111.64	41.34	57.13
Price / Book	5.55	6.63	9.84	6.72
Net Income	-$17.37M	$24.20M	$3.57B	$337.19M
7 Day Performance	-15.49%	-3.24%	-1.16%	0.48%
1 Month Performance	-22.97%	0.53%	3.85%	5.07%
1 Year Performance	21.51%	47.24%	27.40%	34.25%

CytomX Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTMX CytomX Therapeutics	2.4056 of 5 stars	$3.22 +1.9%	$12.10 +275.8%	+25.9%	$537.79M	$76.20M	N/A	170
IDYA IDEAYA Biosciences	2.6307 of 5 stars	$29.10 flat	$50.69 +74.2%	+31.3%	$2.56B	$218.71M	N/A	80	Analyst Forecast
IRON Disc Medicine	1.928 of 5 stars	$66.82 flat	$105.30 +57.6%	+42.5%	$2.55B	N/A	N/A	30	News Coverage
ELVN Enliven Therapeutics	3.2987 of 5 stars	$41.54 flat	$58.40 +40.6%	+85.6%	$2.53B	N/A	N/A	50	News Coverage Analyst Forecast Gap Up
MLYS Mineralys Therapeutics	3.6692 of 5 stars	$29.85 flat	$49.33 +65.3%	+83.8%	$2.46B	N/A	N/A	28	Analyst Forecast Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTMX) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CytomX Therapeutics (CTMX) Competitors

CTMX vs. IDYA, IRON, ELVN, MLYS, and IMNM

How does CytomX Therapeutics compare to IDEAYA Biosciences?

Summary

How does CytomX Therapeutics compare to Disc Medicine?

Summary

How does CytomX Therapeutics compare to Enliven Therapeutics?

Summary

How does CytomX Therapeutics compare to Mineralys Therapeutics?

Summary

How does CytomX Therapeutics compare to Immunome?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTMX vs. The Competition

CytomX Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CytomX Therapeutics (CTMX) Competitors

CTMX vs. IDYA, IRON, ELVN, MLYS, and IMNM

How does CytomX Therapeutics compare to IDEAYA Biosciences?

Do analysts recommend IDYA or CTMX?

Does the media favor IDYA or CTMX?

Do insiders & institutionals believe in IDYA or CTMX?

Which has higher valuation and earnings, IDYA or CTMX?

Which has more risk & volatility, IDYA or CTMX?

Is IDYA or CTMX more profitable?

Summary

How does CytomX Therapeutics compare to Disc Medicine?

Which has stronger valuation & earnings, CTMX or IRON?

Is CTMX or IRON more profitable?

Do insiders and institutionals have more ownership in CTMX or IRON?

Which has more risk & volatility, CTMX or IRON?

Does the media prefer CTMX or IRON?

Do analysts prefer CTMX or IRON?

Summary

How does CytomX Therapeutics compare to Enliven Therapeutics?

Which has higher earnings & valuation, ELVN or CTMX?

Which has more volatility and risk, ELVN or CTMX?

Do institutionals and insiders hold more shares of ELVN or CTMX?

Do analysts prefer ELVN or CTMX?

Does the media prefer ELVN or CTMX?

Is ELVN or CTMX more profitable?

Summary

How does CytomX Therapeutics compare to Mineralys Therapeutics?

Do analysts prefer MLYS or CTMX?

Which has higher earnings and valuation, MLYS or CTMX?

Does the media prefer MLYS or CTMX?

Do insiders & institutionals believe in MLYS or CTMX?

Is MLYS or CTMX more profitable?

Which has more volatility and risk, MLYS or CTMX?

Summary

How does CytomX Therapeutics compare to Immunome?

Do insiders & institutionals have more ownership in CTMX or IMNM?

Which has higher earnings and valuation, CTMX or IMNM?

Does the media favor CTMX or IMNM?

Which has more volatility and risk, CTMX or IMNM?

Do analysts prefer CTMX or IMNM?

Is CTMX or IMNM more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTMX vs. The Competition

CytomX Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools